Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare by partnering with payers. Ms Mamuszka has spent 20 years in biotech, with extensive experience in both drug and diagnostic development, validation, and commercialization. Alva10 is focused on bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies to determine economic impact of diagnostics and create a new value based healthcare model. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Diagnostics are the key to Precision Medicine, but they need to be valued in the healthcare market in order to be successful. For years, diagnostics have been stuck in a downward cycle of value, with poor reimbursement leading to lack of investment, and lack of investment leading to sub-optimal clinical validation, leading back to poor reimbursement. Alva10 is bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies using a proprietary algorithm to determine economic impact of diagnostics and create a new value based healthcare model.
